Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer

International Journal of Colorectal Disease

Volumn 17, Issue 1, 2002, Pages 46-49

  Park, David J ^a   Stoehlmacher, Jan ^a   Zhang, Wu ^a   Tsao Wei, Denice ^a   Groshen, Susan ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Capecitabine; Colorectal cancer; Fluoropyrimidine chemotherapy; Polymorphism; Thymidylate synthase gene

Indexed keywords

CAPECITABINE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; FOOT DISEASE; HAND DISEASE; HOMOZYGOSITY; HUMAN; MALE; METASTASIS; NAUSEA; PILOT STUDY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VOMITING; COLORECTAL TUMOR; GENETIC POLYMORPHISM; GENETICS; GENOTYPE;

ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; THYMIDYLATE SYNTHASE;

EID: 0036355046     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003840100358     Document Type: Article

References (19)

1. Heidelberger C, Chaudhuri NK, Danenberg PV, Mooren D, et al (1957) Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature 179:663-666
2. Brito RA, Medgyesy D, Zukowski TH, Royce ME, et al (1999) Fluoropyrimidines: a critical evaluation. Oncology 57 [Suppl 1]:2-8
3. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274-1281
4. Danenberg PV (1997) Thymidylate synthase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473:73-92
5. Nobuyuki H, Masahiko C, Ryushi N, Keiichi T (1993) Characterization of the regulatory sequences and nuclear factors that function in cooperation with the promoter of the human thymidylate synthase gene. Biochim Biophys Acta 1216:409-416
6. Pullarkat, ST, Stoehlmacher J, Ghaderi V Xiong Y, et al (2001) Thymidylate synthase gene polymorphism determines clinical outcome of patients with colorectal cancer treated with fluoropyrimidine chemotherapy. Pharmacogenomics J 1:65-70
7. Ulrich CM, Bigler J, Velicer CM, Greene EA, et al (2000) Searching expressed sequence tag database: discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9:4583
8. Mehta CR, Patel NR (1983) A network algorithm for performing Fisher's exact test in rXc contingency tables. J Am Stat Assoc 78:427-434
9. Cutsem EV, Findlay M, Osterwalder B, Kocha W, et al (2000) Capecitabine, an oral fluoropyrimidine with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18:1337-1345:2000
10. Leichman CG, Lenz H, Leichman L, Danenberg K, et al (1997) Quantitation of intramural thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223-3229
11. Kawakami K, Omura K, Kanehira E, Wanatabe Y (1999) Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19:3249-3252
12. Horie N, Aiba H, Oguro K, Hojo H, Takeishi K (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191-197
13. Ishikawa T, Utoh M, Sawada N, Nishida M, et al (1998) Tumor selective delivery of 5-FU by capecitabine, a new oral fluorpyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 55:1091-1097
14. Cao S, Lu K, Ishitsuka H, Rustum YM (1997) Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. Proc Am Soc Clin Oncol 795
15. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H (1998) Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 58:685-690
16. Salonga D, Danenberg KD, Johnson M, Metzger R, et al (2000) Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327
17. Marsh S, Collie-Duguid ES, Li T, Liu X, McLoed HL (1999) Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58:310-312
18. Twelves C, Harper P, Van Cutsem E, et al (1999) A phase III trial (S014796) of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 15:206a
19. Cox JV, Pazdur R, Thibault A, et al (1999) A phase III trial of Xeloda (capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 18:256a